SCHEMBL13739552

SCHEMBL13739552

Cc1sc(-c2ccc(Cl)cc2)cc1C(=O)CCl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.55
ALDH1A1 P00352 7/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
MAPT P10636 7/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 2/20 0.43
GFER P55789 1/20 0.43
IKBKB O14920 2/20 0.43
NPC1 O15118 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13832852 0.79 USP14 (0.56) ALDH1A1MAPTMEN1KMT2ARAB9A
SCHEMBL13832856 0.76 USP14 (0.47) ALDH1A1MAPTRAB9ASMN1; SMN2CHEK1
SCHEMBL13832712 0.76 SMN1; SMN2 (0.43) GSK3BALDH1A1MAPTPOLBRAB9A
SCHEMBL6788403 0.73 GSK3B (0.70) GSK3BALDH1A1MAPK1HIF1AMAPT
SCHEMBL29104355 0.73 HPGD (0.51) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL6795205 0.72 GSK3B (1.00) GSK3BALDH1A1MAPK1HIF1AMAPT
SCHEMBL12777778 0.71 MAPT (0.45) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL10850438 0.68 ALDH1A1 (0.67) GSK3BALDH1A1MAPK1HIF1AMAPT
SCHEMBL5770536 0.68 MAPT (0.58) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL31181950 0.67 GAA (0.54) ALDH1A1MAPTPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180189-B2 Proteostasis regulators Kineta, Inc. (US) 2024-12-31 US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 US disclosed
EP-3552664-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2019-10-16 EP disclosed
EP-3552664-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2019-10-16 EP disclosed
EP-2707101-B1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS INC (US) 2019-02-13 EP disclosed
EP-2707101-B1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS INC (US) 2019-02-13 EP disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
EP-2707101-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2014-03-19 EP disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299270-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885MAPK1 3492/4885
US-20170247355-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885MAPK1 3492/4885
US-12180189-B2 Proteostasis regulators PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885MAPK1 3492/4885
US-20120316193-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885MAPK1 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.